0001209191-23-043443.txt : 20230726
0001209191-23-043443.hdr.sgml : 20230726
20230726170802
ACCESSION NUMBER: 0001209191-23-043443
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230724
FILED AS OF DATE: 20230726
DATE AS OF CHANGE: 20230726
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Klearman Micki
CENTRAL INDEX KEY: 0001864934
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38542
FILM NUMBER: 231114381
MAIL ADDRESS:
STREET 1: C/O KEZAR LIFE SCIENCES, INC.
STREET 2: 4000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kezar Life Sciences, Inc.
CENTRAL INDEX KEY: 0001645666
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473366145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-822-5600
MAIL ADDRESS:
STREET 1: 4000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-07-24
0
0001645666
Kezar Life Sciences, Inc.
KZR
0001864934
Klearman Micki
C/O KEZAR LIFE SCIENCES, INC.
4000 SHORELINE COURT, SUITE 300
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
0
Stock Option (Right to Buy)
5.94
2023-07-24
4
D
0
52000
D
2031-05-31
Common Stock
52000
0
D
Stock Option (Right to Buy)
2.28
2023-07-24
4
A
0
52000
A
2031-05-31
Common Stock
52000
52000
D
Stock Option (Right to Buy)
5.59
2023-07-24
4
D
0
26000
D
2031-06-27
Common Stock
26000
0
D
Stock Option (Right to Buy)
2.28
2023-07-24
4
A
0
26000
A
2031-06-27
Common Stock
26000
26000
D
Stock Option (Right to Buy)
4.80
2023-07-24
4
D
0
26000
D
2032-06-15
Common Stock
26000
0
D
Stock Option (Right to Buy)
2.28
2023-07-24
4
A
0
26000
A
2032-06-15
Common Stock
26000
26000
D
One thirty-sixth (1/36th) of the shares vested or shall vest on a monthly basis following the vesting commencement date of June 1, 2021, subject to the Reporting Person continuing to provide service through each such date.
On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.
Fully vested and exercisable.
/s/ Marc Belsky, Attorney-in-Fact
2023-07-26